An amazing first successful clinical trial of a potential cure for HIV has made headlines across the globe.
IMPORTANT UPDATE: The source in which KWIR Media reference about the “promising HIV cure,” LGBTQ Nation, has released a following up article claiming that leading scientists have doubts about the claims made by the Gammora drug press release communicated in the initial article.
The study wasn’t peer-reviewed and a press release claims that there were no side effects to the treatment.
“The HIV world has seen quackery in different forms for decades – sadly this smacks of more of it,” said Dr. Francois Venter, Deputy Executive Director of the Wits Reproductive Health and HIV Institute at the University of the Witwatersrand.
He cited the “over-the-top biological claims that appear in public before the formal literature” and said the press release “should be viewed with deep skepticism.”
“I looked at the press report and the unsophisticated company website, and even if you believe their claims, they are many years away from testing them.”
Moreover, the press release didn’t actually promise anything like a cure. A 99% reduction in viral load is already achievable with traditional antiretroviral therapy, and Gammora’s 99% reduction was only achieved in the part of the study where it was paired with traditional antiretroviral therapy.
Click here to read the full article Leading scientists are expressing doubt over the new ‘potential cure’ for HIV.
According to an LGBTQ Nation article released on November 13, 2018, the promising Gammora drug showed impressive signs of virus elimination.
A new medication has shown amazing promise in its first clinical trial. The drug, Gammora, eliminated 99% of the virus after just four weeks of treatment.
In the first phase of the trial, nine HIV infected patients in Uganda were given different doses of Gammora for 4-5 weeks. Most of those in the trial showed up to a 90% reduction in their viral load in the first four weeks.
In the second phase, held just two weeks after the first, these patients were given Gammora in conjunction with an additional retroviral medication for 4-5 weeks. This time, most of the patients showed up to a 99% reduction.
Also during the full length of the study, patients showed no side effects from the drug, showing that the medication is safe for consumption.
Patients in the study also saw an increase in healthy T cells, important parts of the body’s immune system.
The doctors overseeing the study were even surprised themselves by the findings and are eager to continue their research.
“These first clinical results were beyond our expectations and promise hope in finding a cure for a disease that’s been discovered over 35 years,” says Dr. Esmira Naftali, the head of development for Zion Medical.
“Given the limited nature of this study, we are excited to prove the efficiency of our drug in Phase 2b with a greater number of participants over a longer period of time.”
Phase 2b of trials will begin in the coming months, and will involve 50 patients in treatment for two to three months.
The LGBTQ Nation article, Potential cure for HIV just aced its first clinical trial & is moving forward, also provides some great insight into the drug itself.
Gammora is a synthetic peptide compound derived from the HIV enzyme integrase. That enzyme is responsible to inserting HIV’s genetic material into the DNA of an infected cell. Gammora overwhelms that process, leading to the self-destruction of the infected cell.
This works substantially different than other current medications against HIV that prevent the transmission of the virus but do not cure the actual infection.
The medication has only recently reached clinical trials, but has been under study for more than a decade. This clinical trial was held between July and August of this year.